大细胞肺癌的病理和治疗的研究进展  

Research progress in the pathology and treatment of large cell lung carcinoma

作　　者：杨阳[1] 张志远 傅炜萍[1] YANG Yang;ZHANG Zhiyuan;FU Weiping(Department of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Kunming Medical University,Kunming 650000,China)

机构地区：[1]昆明医科大学第一附属医院呼吸与危重症医学科,昆明650000

出　　处：《实用医学杂志》2023年第5期544-549,共6页The Journal of Practical Medicine

基　　金：云南省高层次卫生技术人才培养(编号:D-201662);昆明医科大学研究生创新基金(编号:2022S217)。

摘　　要：大细胞肺癌(large cell lung carcinoma,LCLC)是一种未分化的非小细胞肺癌,其病理特征缺乏腺癌、鳞癌和小细胞癌的细胞形态、组织结构及免疫标记物。LCLC发病率低且预后差。LCLC占肺癌手术标本不超过1%。全身综合治疗是其主要的治疗方式。本文结合近年来国内外关于LCLC病理诊断和治疗方面的研究进展进行综述,为下一步研究和治疗提供参考方向。Large cell lung carcinoma(LCLC)is an undifferentiated non⁃small cell lung cancer that lacks the morphological and immunological markers of adenocarcinoma,squamous cell carcinoma,and small cell carci⁃noma.LCLC has a low incidence and poor prognosis.The incidence of LCLC is less than 1%of lung cancer surgical specimens.Systemic comprehensive treatment is the main treatment.This article reviews the research progress in the pathological diagnosis and treatment of LCLC in recent years,aiming to provide a reference for further research and treatment.

关 键 词：大细胞癌 肺 诊断 治疗 

分 类 号：R73[医药卫生—肿瘤]